Researchers track heart safety of prostate cancer drug in real patients
NCT ID NCT06010914
Summary
This study is collecting safety information on an approved prostate cancer drug combination in Japanese men. Researchers will observe about 100 participants already receiving darolutamide plus standard hormone therapy and chemotherapy in their normal medical care. The main goal is to learn about heart-related side effects and other safety issues that occur during real-world treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Many Locations
Multiple Locations, Japan
Conditions
Explore the condition pages connected to this study.